NCT03073304

Brief Summary

The primary aim of this study is to investigate the possibility to replace an erythrocyte based prime solution with a crystalloid based prime solution while maintaining metabolic function. Secondary also to study if potentially reduced immunological influence is obtained during hyper thermic isolated limb perfusion with a crystalloid based prime solution.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 24, 2017

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

February 28, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 8, 2017

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 20, 2018

Completed
Last Updated

January 26, 2024

Status Verified

January 1, 2024

Enrollment Period

12 months

First QC Date

February 28, 2017

Last Update Submit

January 25, 2024

Conditions

Keywords

isolated limb perfusion

Outcome Measures

Primary Outcomes (1)

  • Lactate level during and after perfusion.

    Lactate level during and after perfusion.

    1 hour

Secondary Outcomes (5)

  • Arterial oxygen and regional venous oxygen saturation during and after completion of perfusion.

    1 hour

  • Hematocrit during and after completion of perfusion.

    1 hour

  • Oxygen extraction during, and after perfusion.

    1 hour

  • Complications

    30 days

  • Immunological effects

    30 days

Study Arms (2)

Control

ACTIVE COMPARATOR

Erythrocyte based prime solution

Drug: Erythrocyte based prime solution

Intervention

EXPERIMENTAL

Crystalloid based prime solution

Drug: Crystalloid based prime solution

Interventions

Crystalloid based prime solution

Intervention

Erythrocyte based prime solution

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The patient scheduled for treatment with isolated hyperthermic perfusion
  • Age over 18 years.
  • Signed informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sahlgrenska University Hospital

Gothenburg, 413 45, Sweden

Location

Related Publications (1)

  • Corderfeldt Keiller A, Holmen A, Hansson C, Ricksten SE, Bragadottir G, Olofsson Bagge R. Non-invasive and invasive measurement of skeletal muscular oxygenation during isolated limb perfusion. Perfusion. 2023 Jul;38(5):1019-1028. doi: 10.1177/02676591221093201. Epub 2022 May 16.

MeSH Terms

Conditions

MelanomaSarcoma

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue DiseasesNeoplasms, Connective and Soft Tissue

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

February 28, 2017

First Posted

March 8, 2017

Study Start

February 24, 2017

Primary Completion

February 20, 2018

Study Completion

April 20, 2018

Last Updated

January 26, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations